- Home
- PDSB vs OTLK Comparison
PDSB vs OTLK Comparison
Compare PDSB & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDSB
- OTLK
- Stock Information
- Founded
- PDSB 2005
- OTLK 2010
- Country
- PDSB United States
- OTLK United States
- Employees
- PDSB N/A
- OTLK N/A
- Industry
- PDSB Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PDSB Health Care
- OTLK Health Care
- Exchange
- PDSB Nasdaq
- OTLK Nasdaq
- Market Cap
- PDSB 54.5M
- OTLK 48.3M
- IPO Year
- PDSB N/A
- OTLK 2016
- Fundamental
- Price
- PDSB $1.18
- OTLK $1.04
- Analyst Decision
- PDSB Strong Buy
- OTLK Buy
- Analyst Count
- PDSB 2
- OTLK 5
- Target Price
- PDSB $10.00
- OTLK $8.50
- AVG Volume (30 Days)
- PDSB 552.0K
- OTLK 8.0M
- Earning Date
- PDSB 11-13-2025
- OTLK 08-14-2025
- Dividend Yield
- PDSB N/A
- OTLK N/A
- EPS Growth
- PDSB N/A
- OTLK N/A
- EPS
- PDSB N/A
- OTLK N/A
- Revenue
- PDSB N/A
- OTLK $1,505,322.00
- Revenue This Year
- PDSB N/A
- OTLK N/A
- Revenue Next Year
- PDSB N/A
- OTLK $484.88
- P/E Ratio
- PDSB N/A
- OTLK N/A
- Revenue Growth
- PDSB N/A
- OTLK N/A
- 52 Week Low
- PDSB $0.85
- OTLK $0.79
- 52 Week High
- PDSB $4.29
- OTLK $6.98
- Technical
- Relative Strength Index (RSI)
- PDSB 46.25
- OTLK 36.87
- Support Level
- PDSB $1.12
- OTLK $1.02
- Resistance Level
- PDSB $1.26
- OTLK $1.19
- Average True Range (ATR)
- PDSB 0.08
- OTLK 0.13
- MACD
- PDSB -0.01
- OTLK -0.01
- Stochastic Oscillator
- PDSB 26.32
- OTLK 60.44
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.